| FASGX | RIDBX | FASGX / RIDBX | |
| Total Expense Ratio | 0.63 | 1.35 | 47% |
| Annual Report Gross Expense Ratio | 0.66 | 1.35 | 49% |
| Fund Existence | 34 years | 24 years | - |
| Gain YTD | 18.821 | 8.740 | 215% |
| Front Load | N/A | N/A | - |
| Min. Initial Investment | 0 | 250 | - |
| Min. Initial Investment IRA | N/A | N/A | - |
| Net Assets | 7.71B | 140B | 6% |
| Annual Yield % from dividends | 1.58 | 2.85 | 55% |
| Returns for 1 year | 14.06 | 8.02 | 175% |
| Returns for 3 years | 42.65 | 24.52 | 174% |
| Returns for 5 years | 33.11 | 23.95 | 138% |
| Returns for 10 years | 90.24 | 46.10 | 196% |
| 1 Day | |||
|---|---|---|---|
| MFs / NAME | Price $ | Chg $ | Chg % |
| MCYSX | 13.09 | 0.07 | +0.54% |
| NYLI Candriam Emerging Markets Eq Cl R6 | |||
| GSRRX | 10.67 | 0.05 | +0.47% |
| Goldman Sachs Rising Dividend Gr R | |||
| GSPQX | 18.30 | 0.05 | +0.27% |
| Goldman Sachs US Eq Div and Premium C | |||
| TRBCX | 213.17 | 0.44 | +0.21% |
| T. Rowe Price Blue Chip Growth | |||
| NRIFX | 22.56 | 0.03 | +0.13% |
| Nuveen Real Asset Income R6 | |||